Pazufloxacin

Summary

Pazufloxacin (CHEMBL240163) is a phase-3 clinical-stage small molecule (ATC J01MA18); indicated across 3 conditions including bacterial conjunctivitis and bacterial infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01MA18
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 318.3 Da · C16H15FN2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL240163
Name	Pazufloxacin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65957
ATC	J01MA18
Molecular formula	C16H15FN2O4
Molecular weight	318.3
InChIKey	XAGMUUZPGZWTRP-ZETCQYMHSA-N

SMILES: C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O

IUPAC name: (2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid

Also known as: Pazufloxacin, Pazufloxacine, Pazufloxacino, T-3761, SID26719888, SID49681761, SID50112787, PAZUFLOXACINE, SID144206084, SID170465985, PAZUFLOXACIN, PAZUFLOXACIN MESYLATE

Parent form; salt/anhydrous children: CHEMBL3764913

Patent coverage: 1,250 distinct patent families (4,594 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,552 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Lysine-specific demethylase 4E, Streptokinase A, Fructose-bisphosphate aldolase, Histone-lysine N-methyltransferase 2A.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P10520	5.21	EC50	6203	nM	CHEMBL_ACT_4921686

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial conjunctivitis	3	MONDO:0006668	EFO:1000829
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
otitis media	1	MONDO:0005441	EFO:0004992

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03696342	PHASE3	TERMINATED	Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).